Advertisement

FDA Updates OxyContin Label, Blocks Generic Versions — Physician’s First Watch

Medical News |
April 18, 2013

FDA Updates OxyContin Label, Blocks Generic Versions

By Amy Orciari Herman

The reformulated version of OxyContin, approved in 2010, will receive a label update to note its abuse-deterrent properties, the FDA announced late Tuesday. In addition, the agency said it will not approve generic versions of the original OxyContin.

The reformulated drug's physical and chemical properties should make it harder to inject or snort, according to the FDA. For example, the new tablet is difficult to crush and also forms a viscous gel that cannot easily be injected.

The agency also noted that it will not approve generic versions of the original OxyContin because the product's potential for abuse means its benefits "no longer outweigh its risks." The original OxyContin was pulled from the shelves in 2010.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement